As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.
6 Analysts have issued a HilleVax forecast:
6 Analysts have issued a HilleVax forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -50 -50 |
65%
65%
|
|
| EBIT (Operating Income) EBIT | -52 -52 |
64%
64%
|
|
| Net Profit | -71 -71 |
55%
55%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Robert Hershberg |
| Employees | 14 |
| Founded | 2020 |
| Website | www.hillevax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


